Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1155/2013/704912 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|